Re: Pathologic complete responses, long-term outcomes, and recurrence patterns in HER2-low vs. HER2-zero breast cancer after neoadjuvant chemotherapy: Several issues about HER2 expression and neoadjuvant chemotherapy in breast cancer

Eur J Cancer. 2023 Feb:180:184-185. doi: 10.1016/j.ejca.2022.11.018. Epub 2022 Dec 27.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / pathology
  • Chemotherapy, Adjuvant
  • Female
  • Humans
  • Neoadjuvant Therapy
  • Receptor, ErbB-2 / metabolism
  • Trastuzumab / therapeutic use
  • Treatment Outcome

Substances

  • Trastuzumab
  • Receptor, ErbB-2